Metraipolis › archive › dc_d0647a8ebbad
Clinical characteristics, management, and prognosis of pembrolizumab-induced hypophysitis: retrospective analysis based on case reports — Europe PMC PMID:42358986
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42358986
- DOI
- 10.3389/fimmu.2026.1823373
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T14:30:25.290Z
- SHA-256 of the archived text
573f9a3cdbbc5d761208e8da2361c2e29d0d278696fe2eab5bcca64aa932c517- Stable URL of this page
https://metraipolis.com/documento/dc_d0647a8ebbad
How to cite
Clinical characteristics, management, and prognosis of pembrolizumab-induced hypophysitis: retrospective analysis based on case reports — Europe PMC PMID:42358986 — Europe PMC (en), https://europepmc.org/article/MED/42358986 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d0647a8ebbad (Metraipolis archive dc_d0647a8ebbad, sha256 573f9a3cdbbc5d761208e8da2361c2e29d0d278696fe2eab5bcca64aa932c517)
BibTeX
@misc{dcd0647a8ebbad,
title = {Clinical characteristics, management, and prognosis of pembrolizumab-induced hypophysitis: retrospective analysis based on case reports — Europe PMC PMID:42358986},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42358986},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d0647a8ebbad; sha256 573f9a3cdbbc5d761208e8da2361c2e29d0d278696fe2eab5bcca64aa932c517},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42358986. Agents can read the archived copy with the MCP tool read_document.